CA
VRTX icon

CoreCap Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

CoreCap Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Sell
442
-72
-14% -$31.9K 0.01% 835
2026
Q1 		$230K Sell
514
-6
-1% -$2.8K 0.01% 761
2025
Q4 		$236K Buy
520
+30
+6% +$12.9K 0.01% 739
2025
Q3 		$192K Sell
490
-952
-66% -$398K 0.01% 812
2025
Q2 		$642K Buy
1,442
+641
+80% +$295K 0.03% 455
2025
Q1 		$388K Sell
801
-425
-35% -$198K 0.02% 519
2024
Q4 		$494K Sell
1,226
-6,622
-84% -$3.07M 0.02% 486
2024
Q3 		$3.65M Buy
7,848
+7,154
+1,031% +$3.44M 0.17% 117
2024
Q2 		$325K Sell
694
-1,194
-63% -$518K 0.03% 292
2024
Q1 		$789K Buy
1,888
+395
+26% +$167K 0.04% 329
2023
Q4 		$607K Buy
1,493
+793
+113% +$293K 0.04% 319
2023
Q3 		$243K Buy
+700
New +$245K 0.02% 460
2022
Q4 		$378K Sell
1,309
-4,719
-78% -$1.44M 0.03% 407
2022
Q3 		$1.75M Buy
6,028
+254
+4% +$73.1K 0.15% 126
2022
Q2 		$1.63M Buy
+5,774
New +$1.55M 0.13% 129
2022
Q1 		– Sell
-372
Closed -$82K – 2070
2021
Q4 		$82K Buy
+372
New +$72.3K 0.01% 832

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

CoreCap Advisors's VRTX Position: Q2 2026 in Review

CoreCap Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, selling an estimated $31.9K and leaving 442 shares worth $220K. The position accounts for 0.01% of the portfolio, ranked #835.

CoreCap Advisors first reported a position in VRTX in Q4 2021 and has held it in 16 quarters since. The position peaked at $3.65M in Q3 2024. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • CoreCap Advisors held 442 shares of Vertex Pharmaceuticals worth $220K as of Q2 2026.
  • CoreCap Advisors sold 72 Vertex Pharmaceuticals shares in Q2 2026, an estimated $31.9K.
  • Vertex Pharmaceuticals made up 0.01% of CoreCap Advisors's portfolio in Q2 2026, its #835 holding.
  • CoreCap Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 16 quarters since.
  • CoreCap Advisors's Vertex Pharmaceuticals position peaked at $3.65M in Q3 2024.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.